Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis has agreed to buy Myricx Bio, a small British oncology company, for up to $1.5bn, adding an early-stage but potentially significant technology to a cancer pipeline the industry keeps racing to expand. The Swiss group will pay $1.1bn upfront, with up to $400m more tied to milestones, in a deal that fits the pattern […]<br /> This story continues at The Next Web [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
FDA approves at-home pap smear alternative device for cervical cancer screening
The Food and Drug Administration has approved a new device called the Teal Wand, which its creator describes as an "at-home vaginal sample self-collection device for cervical cancer screening.&qu [...]
Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science a [...]
Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years
Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the r [...]
A single AI agent conversation can look perfect and still be broken, leaders from LangChain, Conviva and CoreWeave said at VB Transform 2026
A single AI agent conversation can look flawless scored on its own and still point to a broken product. That gap is driving a shift in how enterprises evaluate agents, away from scoring individual tra [...]
OpenAI's acquisition of OpenClaw signals the beginning of the end of the ChatGPT era
The chatbot era may have just received its obituary. Peter Steinberger, the creator of OpenClaw — the open-source AI agent that took the developer world by storm over the past month, raising concern [...]
Stanford researchers will discuss their agentic 'scientists' that are on course to reshape drug discovery at VB Transform 2026
Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the next through disconnected workflows that result in knowledge loss during ea [...]